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Abstract 9 
Most of the computational models of drug transport in vascular tumours assume a uniform distribution of 10 
blood vessels through which anti-cancer drugs are delivered. However, it is well known that solid 11 
tumours are characterised by dilated microvasculature with non-uniform diameters and irregular 12 
branching patterns. In this study, the effect of heterogeneous vasculature on drug transport and uptake is 13 
investigated by means of mathematical modelling of the key physical and biochemical processes in drug 14 
delivery. An anatomically realistic tumour model accounting for heterogeneous distribution of blood 15 
vessels is reconstructed based on magnetic resonance images of a liver tumour. Numerical simulations are 16 
performed for different drug delivery modes, including direct continuous infusion and thermosensitive 17 
liposome-mediated delivery, and the anti-cancer effectiveness is evaluated through changes in tumour cell 18 
density based on predicted intracellular concentrations. Comparisons are made between regions of 19 
different vascular density, and between the two drug delivery modes. Our numerical results show that 20 
both extra- and intra-cellular concentrations in the liver tumour are non-uniform owing to the 21 
heterogeneous distribution of tumour vasculature. Drugs accumulate faster in well-vascularised regions, 22 
where they are also cleared out more quickly, resulting in less effective tumour cell killing in these 23 
regions. Compared with direct continuous infusion, the influence of heterogeneous vasculature on anti-24 
cancer effectiveness is more pronounced for thermosensitive liposome-mediated delivery. 25 
Keywords: drug delivery, heterogeneous vasculature, liver tumour, mathematical model, MR imaging, 26 
thermosensitive liposome 27 
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1. Introduction 29 
Microvasculature has a significant influence on the growth, metastasis and drug delivery to tumours. The 30 
organisation of microvasculature depends strongly on the tumour type, its growth rate and location in the 31 
tumour [1]. As a tumour develops, the pre-existing vasculature may become tortuous, enlarged, dilated or 32 
incorporated into the tumour [2, 3]. On the other hand, as a result of angiogenesis occurring at the 33 
capillary level, neovascularization can originate from venules within the tumour and in the host tissue. 34 
The structures of newly formed microvessels are irregular, especially in fast growing tumours [2, 3]. 35 
For a solid tumour at a specific growth stage, the distribution of microvessels is spatially heterogeneous. 36 
In tumours with peripheral vascularisation, the centre is often poorly perfused and vasculatures are 37 
predominantly located near the boundaries, resulting in the formation of a necrotic core. This may also 38 
occur when a tumour is fully grown and invades into its host tissue. In tumours with central 39 
vascularisation, microvessels may proliferate to form a tree-like structure in the centre, resulting in higher 40 
vessel density [4, 5]. 41 
Previous numerical studies of drug transport have typically assumed a homogeneous distribution of 42 
microvasculature in non-necrotic regions. A numerical platform for studying drug transport in solid 43 
tumours was established by Baxter and Jain [6-8] with a focus on understanding the influences of various 44 
factors on the concentration of antibodies in the extracellular space. El-Karech [9] and Eikenberry [10] 45 
used mathematical modelling to determine doxorubicin concentration in the extra- and intra-cellular space 46 
with an idealised model and a tumour cord model, respectively. Goh et al. [11] investigated  drug 47 
concentration in a 2-D hepatoma model which was assumed to have a uniformly distributed 48 
microvasculature in the tumour region excluding the necrotic core,. A 3-D computational model was 49 
applied to murine sarcoma by Zhao et al. [12] in order to study the effects of spatial variation of fluid 50 
filtration rate and vascular permeability on tumour microenvironment and drug transport, without 51 
incorporating the effect of anti-cancer drug on tumour cells.     52 
In the present study, an improved mathematical model is applied to a realistic model of human liver 53 
tumour, with an aim to determine the effect of heterogeneous micro-vessel density on drug concentrations 54 
in the extra- and intra-cellular space as well as the effectiveness of anti-cancer treatment. The 55 
mathematical model incorporates the key physical and biological drug delivery processes, including the 56 
time-dependent plasma clearance, liposome and drug transport across the blood and lymphatic vessel 57 
walls, drug binding with proteins, lymphatic drainage, interactions with normal tissue, tumour cell uptake, 58 
tumour cell proliferation and physical degradation, as well as cell killing by drugs. The therapeutic 59 
efficacy is evaluated in terms of tumour cell density by directly solving the pharmacodynamics model 60 
based on predicted intracellular drug concentration. Two different drug delivery modes are examined and 61 
compared: continuous infusion of drug in its free form, and thermosensitive liposome-mediated delivery, 62 
where anticancer drugs are encapsulated in the interior of thermosensitive liposomes (TSL), and drug-63 
loaded TSL are administrated via intravenous infusion. TSL are designed to release the encapsulated 64 
drugs upon heating to a designated temperature, which is usually in the range of 42 – 45oC. TSL-mediated 65 
drug delivery has been developed to overcome the limitations of conventional chemotherapy by 66 
prolonging plasma half-life and reducing systemic cytotoxicity. It also has the advantage of being a 67 
localised therapy, as drug release is triggered by heating, which can be targeted at the tumour site. 68 
69 
3 
 
2. Methods 70 
2.1 Model Formulation 71 
The mathematical models consist of the mass and momentum conservation equations for interstitial fluid 72 
flow, mass transfer equations for the free and bound drug, transport equations for liposome encapsulated 73 
drug, as well as equations describing the intracellular drug concentration and pharmacodynamics. Details 74 
of the mathematical equations have been reported previously [13], and a brief summary of these is given 75 
in Appendix. 76 
First, the interstitial fluid flow equations (Table A-1 in Appendix) are solved to provide the basic 77 
biomechanical environment for drug transport. This is followed by solution of the mass transfer equations 78 
for drug transport (Tables A-2 and A-3), which is described schematically in Figure 1(a) and (b) for direct 79 
infusion, and TSL-mediated delivery of doxorubicin, respectively. Briefly, the tumour region consists of 80 
three compartments: blood, extracellular space and tumour cells. Within each compartment, letters F, B 81 
and L represent free, bound and liposome encapsulated doxorubicin, respectively. 82 
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Figure 1. Drug transport with (a) continuous infusion of drug in its free form, and (b) thermosensitive 89 
liposome-mediated drug delivery 90 
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 91 
The dynamics process in drug delivery includes association/disassociation with protein at the rate kas and 92 
kds respectively, drug exchange between blood and extracellular space, and influx/efflux of drugs from 93 
extracellular space to tumour cells. The rate of cell killing is governed by a pharmacodynamics model 94 
based on the predicted intracellular concentration of anticancer drugs (Table A-4 in Appendix). In the 95 
case of TSL-mediated drug delivery, an additional equation describing the transport of liposomes is 96 
needed (Table A-3 in Appendix). Since extra-vascular triggered release is simulated here, drug release at 97 
the rate krel is only included in the extracellular space of tumour. This is a reasonable approximation as the 98 
temperature of extracellular space is always higher than that of blood plasma during hyperthermia [14]. 99 
2.2 Model Geometry 100 
The geometry of a liver tumour is reconstructed from post-contrast MR images acquired from a patient 101 
using a 3.0-Tesla MR scanner (DISCOVERY MR750, GE, Schenectady, New York, USA). Multislice 102 
anatomical images of the liver were acquired in three orthogonal planes with GR sequence at three time 103 
points after systemic infusion of the tracer Gd-DTPA, with each image comprising 256×256 pixels. Other 104 
imaging parameters are given in Table 1.  105 
Table 1. MR imaging parameters 106 
Parameter 
(unit) 
Pixel 
Size 
(mm) 
Field of 
View 
(mm) 
Slice 
Thickness 
(mm) 
Repetition 
Time 
(ms) 
Echo 
Time 
(ms) 
 1.3 420 5.0 3.808 1.808 
 107 
In order to build a 2D model of the tumour and its surrounding normal tissue, a representative transverse 108 
image is chosen, as shown in Figure 2 (a). The chosen section covers the maximum dimension of the 109 
tumour. Image processing is carried out by using Mimics (Materialise HQ, Leuven, Belgium), with the 110 
tumour and its sub-regions being segmented based on pixel intensities and contrast enhancement. It can 111 
be seen that the tumour is located at the corner with a maximum dimension of 41 mm and an area of 112 
9.0×10
-4 
m
2
. The tumour is divided into 6 sub-regions based on differences in signal intensities which are 113 
correlated to vessel densities as described later. Region_1 is further divided into two regions in order to 114 
compensate for any potential boundary effect caused by the lack of surrounding normal tissue. The 115 
resulting smoothed contours of the tumour and normal tissues are imported into ANSYS ICEM CFD to 116 
generate computational mesh. The dimensions of the reconstructed model are approximately 118.8 mm 117 
(maximum width) by 126.8 mm (maximum depth), and the area of the normal tissue is 8.7×10
-3 
m
2
.  The 118 
final mesh consists of 88594 triangular elements. This is obtained based on mesh sensitivity tests which 119 
are carried out until the difference in predicted drug concentration between the adopted mesh and a 10-120 
time finer mesh is less than 3%.  121 
 122 
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 124 
Figure 2. Model geometry: (a) MR image of the liver tumour (in red) and its surrounding tissue (in pule 125 
blue); (b) the reconstructed 2-D geometry. 126 
2.3 Model Parameters 127 
A large number of model parameters are required for the computational simulation; these include physical 128 
and transport properties for doxorubicin, liposome, as well as tumour and normal tissues. Essential model 129 
parameters adopted in the present study are the same as those used in our previous work [13]. For brevity, 130 
only differences are described here, and a complete list of model parameters and sources is given in 131 
Appendix (Tables A-6, A-7 and A-8). 132 
Surface Area of Blood Vessels per Unit Volume of Tumour Tissue (S/V) 133 
The concentration of Gd-DTPA tracer in the interstitial fluid is described by: 134 
    pvGdpGd CFCC
V
S
P
dt
dC
 1     (1) 135 
where t is time, P is the permeability of the tracer, S/V is the surface area of blood vessels per unit volume 136 
of tumour tissue, CGd and Cp represent the tracer concentration in the interstitial fluid and blood, 137 
respectively, Fv is the filtration rate from the blood vessels per unit volume of tumour tissue, and σ is the 138 
osmotic reflection coefficient of the tracer (σ = 0.6 [12]). 139 
The average interstitial concentration of Gd-DTPA has been found to be proportional to the relative 140 
enhancement of signal intensity [15]: 141 
1100
0
rTS
SS
CGd

               (2) 142 
where S and S0 represent the signal with and without the tracer, Gd-DTPA, T10 denotes the relaxation time 143 
and r1 is the relaxivity, both of which are constant and can be cancelled out during the evaluation of S/V. 144 
The spatial-mean signal intensity of each tumour region at three different time points is calculated, and 145 
the relative value of surface area of blood vessel per tumour volume, (S/V)
*
, can be obtained by 146 
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interpolation. The ratio of (S/V)
*
 in each tumour region to  the  average  value for the entire tumour region 147 
is then used to calculate values for S/V, by scaling with the standard value from the literature which is 200 148 
cm
-1
. The scaled values are summarized in Table 2 in descending order of microvasculature density.  149 
Table 2. The relative and scaled values of surface area of blood vessel per tumour volume (cm
-1
) 150 
 151 
 Average Region_1 Region_2 Region_3 Region_4 Region_5 Region_6 
(S/V)
*
 776.52 1741.73 860.84 554.73 502.23 428.69 324.48 
S/V 200.00
**
 448.60 221.72 142.88 129.35 110.41 83.57 
** baseline value from literature [11, 16, 17] 152 
Plasma Pharmacokinetics  153 
An exponential decay function is adopted to describe doxorubicin concentration in blood plasma. For 154 
direct continuous infusion, this follows a tri-exponential decay function [9]. For liposome encapsulated 155 
doxorubicin, its plasma pharmacokinetics is described by a 2-exponential decay function [18]. The effect 156 
of binding of free doxorubicin with proteins has been taken into account in the same way as reported 157 
previously [13]. Relevant equations are given in Table A-5 in Appendix. 158 
2.4 Numerical Methods and Boundary Conditions 159 
The mathematical equations are solved by means of a finite volume based computational fluid dynamics 160 
(CFD) code, ANSYS FLUENT, together with tailor-made routines using the User Defined Scalar (UDS) 161 
function. The second order UPWIND scheme is adopted for spatial discretization, while temporal 162 
discretization is achieved by employing the second order implicit backward Euler scheme. Regarding 163 
boundary conditions, the only external boundary is the outer surface of the normal tissue, where a zero 164 
relative pressure is prescribed. All variables at the internal boundaries between the tumour and normal 165 
tissue and between different tumour regions are assumed to be continuous. The governing equations for 166 
interstitial fluid flow are solved first, and the resolved pressure and velocity fields in tumour and normal 167 
tissues are then used to solve the mass transfer equations for drug transport. A fixed time-step of 10 168 
seconds is chosen following a time-step sensitivity test.  The convergence criteria for residual tolerances 169 
are 1×10
-5
 for momentum equations and 1×10
-8
 for mass transfer equations. 170 
3. Results and Discussion 171 
Interstitial fluid pressure (IFP) plays an important role in determining the transport of drug in tumours. 172 
IFP is obtained by solving the governing equations for interstitial flow (Table A-1 in Appendix) for the 173 
entire tumour region and its surrounding normal tissue, subject to the boundary conditions described 174 
above and a vascular pressure of 2080 Pa. As shown in Figure 3, there is no discernable difference among 175 
different tumour regions, although IFP in the tumour is much higher than that in the normal tissue. The 176 
observation that IFP is not sensitive to tumour microvasculature distribution is consistent with the results 177 
of Baxter and Jain [7] who found that even the presence of a necrotic core had virtually no effect on the 178 
IFP profile, unless the necrotic core size is greater than 90% of the tumour size. This is because in regions 179 
except for a thin layer close to the outer boundary of the tumour, IFP equilibrates with the effective 180 
vascular pressure, which is given by  ivpvp   ; refer to Appendix for definition of symbols and 181 
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parameter values. Based on the model parameters adopted in this study, the effective vascular pressure is 182 
1533.88 Pa; this is reached in all tumour regions except region_1 and region_2, where the mean IFP is 183 
slightly lower. This means that there is no net filtration between the microvessels and interstitium in 184 
regions 3-6 which are surrounded by regions 1 and 2. On the other hand, the rather uniform IFP in the 185 
interior of tumour implies that pressure-induced convection of interstitial fluid is weak there, and 186 
convective drug transport in the interstitium occurs mainly within a thin layer at the tumour/normal tissue 187 
interface, where there is a steep pressure gradient.  188 
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 189 
Figure 3. Interstitial fluid pressure distribution in tumour and normal tissues.  190 
 191 
 192 
3.1 Direct Continuous Infusion 193 
For direct infusion of doxorubicin, a total dose of 50 mg/m
2
 [19] is administrated into blood within 2 194 
hours [9]. Figure 4 shows the spatial distribution of free doxorubicin at different time points in the tumour. 195 
It is clear that extracellular concentration of doxorubicin is non-uniform, which is not surprising since the 196 
transport of drug is channelled through blood vessels, and as such, vasculature density is expected to have 197 
a strong influence on the spatial distribution of drug. Since the difference in extra- and intra-cellular 198 
concentrations between sub-regions 1_1 and 1_2 is very small these sub-regions are combined and 199 
referred to as region_1 in the following discussion. 200 
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 201 
Figure 4. Spatial distribution of free doxorubicin extracellular concentration in tumour regions.  202 
Figure 5 shows the variation of extracellular concentration of free and bound doxorubicin in the liver 203 
tumour and each of its sub-regions of different vessel densities. In all regions, the predicted concentration 204 
increases during the infusion period, when doxorubicin is administrated continuously into the circulatory 205 
system. After the end of administration, both free and bound doxorubicin concentrations start falling 206 
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immediately. There are obvious differences in drug concentration in different tumour regions until at 207 
approximately 12 hour, when uniform doxorubicin concentrations are reached in all tumour regions (also 208 
demonstrated in Figure 4). The rate of change of doxorubicin concentration is slower in regions with low 209 
vessel density (e.g. region_6), owing to reduced drug exchange between plasma and interstitial fluid as a 210 
result of sparse vasculature. 211 
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 212 
Figure 5. Spatial mean doxorubicin extracellular concentration in tumour as a function of time. (a) Free 213 
doxorubicin, and (b) bound doxorubicin (total dose = 50 mg/m
2
).  214 
Intracellular concentration also displays a non-uniform pattern among tumour regions of different vessel 215 
densities. As shown in Figure 6(a), the rate of change of intracellular concentration is slower and peak 216 
concentration is lower in poorly vascularised regions, similar to the pattern observed for extracellular 217 
concentration. The predicted anti-cancer effectiveness, assessed based on variation in the percentage of 218 
tumour cells (Figure 6(b)), suggests that cell killing is more effective in well-vascularised regions in the 219 
first few hours, but the trend is reversed thereafter. However, the difference among the various regions is 220 
small, with the maximum difference being 3% between region_1 (high vessel density) and region_6 (low 221 
vessel density).  A parametric sensitivity study confirms that the qualitative trend presented here is not 222 
altered by changes in infusion duration or dose level. 223 
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 224 
Figure 6. Spatial mean (a) intracellular concentration and (b) percentage of tumour cells as a function of 225 
time (total dose = 50 mg/m
2
). 226 
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3.2 TSL Encapsulated Doxorubicin 227 
For TSL-mediated delivery, it is assumed that there is no release of doxorubicin until the temperature 228 
exceeds 42˚C. Heating begins at 24 hour following the administration of TSL-doxorubicin (simulating 229 
extravascular release), and the simulated heating duration is 1 hour [9]. Given that the temperature of 230 
blood plasma is always lower than that of the surrounding tissue during hyperthermia [14], no 231 
doxorubicin is assumed to be released in blood plasma.  232 
Concentrations of encapsulated doxorubicin in blood plasma and tumour interstitial space are shown in 233 
Figure 7. Following drug administration, encapsulated doxorubicin concentration in tumour increases 234 
rapidly during the initial period and reaches equilibrium with blood plasma after 5-16 hours depending on 235 
tumour vascular density. It then follows the intravascular concentration curve until a sharp fall at 24 hour 236 
when TSL particles are heated to 42˚C, causing a rapid release of doxorubicin. After heating stops at 25 237 
hour, the encapsulated doxorubicin concentration starts to rise again and recovers to a new equilibrium 238 
level with blood plasma.  239 
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 240 
Figure 7. Concentrations of liposomal encapsulated doxorubicin in blood plasma and in tumour over the 241 
treatment duration.  242 
It is clear from these results that the heterogeneous blood vessel distribution has a strong influence on 243 
doxorubicin concentration in tumour. The rate of change in concentration is faster in regions that are well 244 
perfused. After heating, extracellular concentration of encapsulated doxorubicin is determined by the rate 245 
of doxorubicin release and transvascular transport of liposomes. In well-vascularised regions, 246 
transvascular transport is strong, allowing more liposomes to enter; but more encapsulated doxorubicin is 247 
released at the same time. However, the rate of release is slower than that of transvascular transport, so 248 
that the overall effect is dominated by the latter. As a result, region_1 has the highest concentration of 249 
encapsulated doxorubicin after heating, and region_6 has the lowest. 250 
Extracellular concentration profiles of free doxorubicin between 22-36 hours after administration are 251 
shown in Figure 8(a). Since no doxorubicin is released from TSL before heating, both free and bound 252 
doxorubicin concentrations remain at zero during 22-24 hours. Once the temperature reaches 42˚C at the 253 
24 hour, doxorubicin is rapidly released, leading to a sharp increase in concentration (see Figure 8(b) for a 254 
close up view). It is worth noting that the concentration of free doxorubicin is a result of the balance 255 
between the source term which is the amount of drug released from TSL, and the sink terms, which 256 
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include transvascular exchange, binding with protein and tumour cell uptake (as described  in Figure 1(b)). 257 
Detailed contributions of each of these terms are displayed in Figure 9(a), with the net gain of free 258 
doxorubicin given in Figure 9(b). Within a few seconds upon heating, the rapid release of doxorubicin 259 
leads to a peak concentration. However, transvascular transport from the extracellular space also increases, 260 
resulting in a negative net gain (see inset in Figure 9(b)), hence a temporary reduction in extracellular 261 
concentration of free doxorubicin. This lasts for a few minutes only before a positive net gain is restored, 262 
so that free doxorubicin concentration continues to rise until the end of heating. Since no more 263 
doxorubicin is released from the 25
 
hour onwards, there is a rapid fall in concentration at this time point 264 
before a gradual reduction thereafter.   265 
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 266 
Figure 8. Extracellular concentration of free doxorubicin as a function of time (a) between 22 and 36 267 
hours, and (b) a close up view at 24 hour. 268 
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 270 
Figure 9. Spatial mean rate of change of free doxorubicin in tumour extracellular space as a function of 271 
time. (a) Contributions of each drug transport process, and (b) net rate of change.  272 
Similar trends are observed for extracellular concentration of bound doxorubicin, shown in Figure 10. 273 
Here the source term accounts for doxorubicin association with protein, and the sink terms account for 274 
drug disassociation with protein and transvascular exchange. Both Figures 8 and 10 show that the rate of 275 
change in extracellular drug concentration is slower in regions of lower vessel density. 276 
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 277 
Figure 10. Extracellular concentration of bound doxorubicin in the tumour as a function of time.  278 
Intravascular concentrations of free and bound doxorubicin are shown in Figure 11(a) and (b), 279 
respectively. Because it is assumed that there is no intravascular release of encapsulated drug, all forms of 280 
doxorubicin enter blood plasma from the interstitial space by convection and diffusion. Results show that 281 
both free and bound doxorubicin concentrations increase during the heating period, and then decrease 282 
from their own peaks when heating is over. Higher peak concentrations are observed in regions of denser 283 
vasculature, where more drugs are transported across the vessel wall. 284 
 285 
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 286 
Figure 11. Intravascular concentration of doxorubicin as a function of time: (a) free doxorubicin, (b) 287 
bound doxorubicin. 288 
The time course of intracellular concentration is shown in Figure 12. It is initially zero until doxorubicin 289 
is released at the 24
 
hour upon heating. During the one hour heating period, there is a rapid increase in 290 
intracellular drug concentration which peaks shortly after the cessation of heating. This is followed by a 291 
reduction in intracellular concentration at varying rates depending on vascular density in the tumour 292 
region, with slower reduction in regions of lower vessel density.  293 
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 294 
Figure 12. Spatial mean intracellular concentration of doxorubicin in tumour regions as a function of time.  295 
The anti-cancer effectiveness is evaluated by calculating changes in the percentage of tumour cells using 296 
a pharmacodynamics model described previously [13]. As can be seen in Figure 13, the percentage of 297 
tumour cells begins to decline at the 24
 
hour when drug is released from TSL upon heating. There is a 298 
rapid cell killing phase in the first few hours after heating in all tumour regions, but the duration of this 299 
phase depends strongly on the density of microvasculature. This is followed by a slower cell killing phase 300 
which lasts for approximately 2 hours.  With further reduction in intracellular concentration, the rate of 301 
cell killing and physiological degradation is overtaken by that of cell proliferation, and as a result, the 302 
percentage of tumour cells begins to increase. Results in Figure 13 suggest that better anti-cancer 303 
effectiveness is achieved in regions of lower vascular density.  304 
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 305 
Figure 13. Percentage of tumour cells in different regions of tumour as a function of time.  306 
Spatial distributions of tumour cell density at different time points are shown in Figure 14. There is no 307 
difference among tumour regions at the 25
 
hour, as the heating period is dominated by the rapid release of 308 
doxorubicin which results in a uniformly high drug concentration in all tumour regions. After the end of 309 
heating, no more doxorubicin is released, and as a result, the level of intracellular drug concentration is 310 
strongly influenced by the rate at which doxorubicin is lost from the extracellular space, which in turn 311 
depends on local vascular density. Well-vascularised regions (e.g. region_1) lose doxorubicin more 312 
quickly through diffusion back to the plasma than poorly vascularised regions (e.g. region_6), and hence 313 
less effective tumour cell killing in the former.  314 
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Figure 14. Spatial distribution of tumour cell density for liposomal delivery.  315 
For TSL-mediated drug delivery, the predicted anti-cancer efficacy can be influenced by a number of 316 
factors; these include release mode (intra- or extra-vascular triggered release), heating schedule (e.g. the 317 
duration and timing of heating) and drug release rate. To test the sensitivity of the results to these factors, 318 
simulations have been repeated for a longer heating duration (2 hours), an early timing of heating (at the 8 319 
hour following TSL administration), and a faster release of doxorubicin from TSL (at 0.0541 s
-1
 based on 320 
data in [20]). Since the mathematical model does not include intravascular release, it is not possible to 321 
compare the effect of different release modes. Results corresponding to 2-hour heating duration are 322 
presented in Figure 15, which shows the same qualitative trend as that obtained for 1-hour heating, i.e. 323 
more effective tumour cell killing in regions of lower vascular density, although with 2-hour heating there 324 
is ~5% improvement in anti-tumour effectiveness. Results for an early heating at the 8 hour are virtually 325 
identical to those for heating at the 24 hour, except that the timing is brought forward accordingly. With a 326 
faster release of doxorubicin from TSL, the overall anti-tumour effectiveness is improved but the 327 
qualitative trend remains the same. These results are not presented here owing to space limitation. 328 
Compared with continuous infusion of non-encapsulated drugs, the anti-cancer effectiveness for TSL-329 
mediated delivery is more sensitive to the heterogeneous distribution of microvasculature. This is mainly 330 
attributed to the discontinuous release of doxorubicin from TSL during a treatment period, i.e. rapid 331 
release upon heating and no release outside the heating period. Consequently, the level of intracellular 332 
drug concentration cannot be sustained after heating is over, and the rate at which intracellular 333 
concentration falls is strongly dependent on vasculature density. This dependence results in a more rapid 334 
fall in intracellular concentration in well-vascularised regions, leading to less effective cell killing 335 
compared to poorly-vascularised regions where intracellular concentration falls more slowly, allowing for 336 
more exposure time to trigger cell killing. On the other hand, continuous infusion of non-encapsulated 337 
drug ensures a constant supply of drugs during the entire treatment period. In this case, cell killing is more 338 
effective in well-vascularised regions in the first few hours, but the trend is reversed thereafter. The 339 
quantitative effect of vascular density on the resultant cell killing is not as pronounced as for TSL-340 
mediated delivery. 341 
 342 
 343 
 344 
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 346 
Figure 15. Spatial mean concentration of anticancer drug and cell killing among tumour regions with 2-347 
hour heating duration. 348 
By incorporating heterogeneous microvascular density in a realistic tumour model, the present study has 349 
provided more insights into the effect of non-uniform distribution of tumour vasculature on drug delivery 350 
to solid tumours. Nevertheless, the mathematical model employed here involves a number of assumptions. 351 
First, the tumour vascular network is treated as a distributed source term in the governing equations 352 
instead of being modelled explicitly. As a result, the effects of intravascular transport and geometric 353 
features of tumour vasculature are not included. While this may be an over-simplification, it is practical 354 
given the lack of information on realistic tumour vasculature geometry and the complexity in direct 355 
modelling of blood flow in a vascular network coupled with interstitial drug transport. Second, a 2D 356 
tumour model is used instead of a full 3D model. Based on our previous comparisons between 2D and 3D 357 
models of a prostate tumour, the 3D effect on spatial-mean parameters, such as intracellular drug 358 
concentration and tumour cell density, is negligible. This is consistent with the work of Teo et al [21] who 359 
found qualitatively similar results between their 2D and 3D models of a brain tumour. 360 
Other assumptions include: (i) signal intensities of tracer Gd-DTPA in post-contrast MR images are used 361 
to calculate vascular density, with the tracer concentration in the plasma being assumed to be proportional 362 
to the relative change in signal intensity. This could be improved by measuring the intravascular 363 
concentration of Gd-DTPA directly in MR imaging [12]. (ii) Tumour temperature is assumed to be 364 
uniform, and changes in temperature during and after heating are ignored. This assumption can be relaxed 365 
by incorporating a bioheat transfer model to predict the temperature distribution in tumour in response to 366 
15 
 
the heating schedule applied. Related to this assumption is the constant release rate, which should be 367 
temperature-dependent, allowing for varied release rates in different regions. (iii) For TSL-mediated 368 
delivery, a fixed heating period of 1 hour at 24 hours after drug infusion are chosen as an example which 369 
may not be the optimal setting for this delivery method. Based on the results presented, it appears that a 370 
longer heating period may help to sustain high levels of intracellular drug concentration, thereby 371 
improving the anti-cancer effectiveness over a given treatment period, and (iv) uniform transport 372 
properties and uniform tumour cell density are assumed in each tumour region.   373 
4. Conclusion 374 
The transport of doxorubicin in a liver tumour with heterogeneous vasculature distribution has been 375 
studied under direct continuous infusion and TSL-mediated delivery. Computational results show that 376 
interstitial fluid pressure is not sensitive to microvessel density in the interior of tumour, implying that 377 
drug transport by pressure-induced convection is weak except in a thin layer close to the tumour boundary. 378 
Compared with continuous infusion of non-encapsulated doxorubicin, the heterogeneous distribution of 379 
tumour vasculature has a greater influence on the effectiveness of tumour cell killing under TSL-mediated 380 
delivery. Our results show that with TSL-mediated delivery and extravascular triggered release, better 381 
anti-cancer effectiveness is achieved in regions of low vasculature density, owing to reduced loss of drugs 382 
to the plasma; and that the qualitative trend is not affected by changes in heating duration, timing of 383 
heating, or release rate, although quantitative differences exist. These findings have important 384 
implications. First, since tumour aggressiveness is manifested through enhanced vascularisation, existing 385 
chemotherapies that work well in treating less aggressive tumours might not be as effective in treating 386 
aggressive, vascularised tumours. Second, the overall effectiveness of TSL-mediated delivery of 387 
chemotherapy drugs is influenced by a number of factors, and future research should aim to design 388 
optimal treatment methods, including heating schedule and release mode, for TSL-mediated delivery of 389 
chemotherapy drugs for the treatment of different types of tumours.   390 
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Appendix 486 
Table A-1. Governing equations for interstitial fluid flow 487 
Continuity  Equation  
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Momentum Equation  
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 489 
Table A-2. Governing equations for drug transport under direct continuous infusion
*
 490 
Free Doxorubicin Concentration in the Interstitial Fluid (Cfe)  
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Bound-Doxorubicin concentration in Interstitial Fluid (Cbe)  
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Intracellular Doxorubicin Concentration (Ci)  
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*
Peb is defined in the same way as Pef in (A-4). 491 
 492 
Table A-3. Governing equations for drug transport under thermo-sensitive liposome-mediated delivery
*
 493 
Liposome Encapsulated Drug Concentration in the Interstitial Fluid (Cle)
**
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Free Doxorubicin Concentration in Blood Plasma (Cfp)  
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Bound Doxorubicin Concentration in Blood Plasma (Cbp)  
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Free Doxorubicin Concentration in Interstitial Fluid (Cfe)  
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*
Bound doxorubicin concentration in interstitial fluid and intracellular concentration are the same as in 494 
Table A-2 495 
**
Pel is defined in the same way as  Pef in (A-4). 496 
 497 
Table A-4. Pharmacodynamics Model  498 
Pharmacodynamics Model  
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 499 
Table A-5. Pharmacokinetics Model 500 
Direct continuous infusion delivery
*
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Liposome encapsulated drug delivery  
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75% of doxorubicin binds with protein    501 
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Table A-6. Parameters for tumour and normal tissues 
 511 
Symbol Parameter Unit 
Tumour 
Tissue 
Normal 
Tissue 
Source 
S/V 
surface area of vessels per unit volume of 
tissue 
m
-1 
20000 7000 [6, 16, 20] 
Kv 
hydraulic conductivity of the microvascular 
wall 
m/Pa·s 2.10×10
-11
 2.70×10
-12
 [6, 7] 
ρ density of interstitial fluid kg/m3 1000 1000 
estimated  
[11] 
µ dynamic viscosity of interstitial fluid kg/m·s 0.00078 0.00078 
estimated 
[11] 
1/κ permeability of the interstitial space m-2 4.56×1016 2.21×1017 [6, 11, 21] 
pv intravascular pressure Pa 2080 2080 [6, 22] 
πv osmotic pressure of the plasma Pa 2666 2666 [6, 22] 
πi osmotic pressure of interstitial fluid Pa 2000 1333 [6, 11] 
σp 
average osmotic reflection coefficient for 
plasma proteins 
 0.82 0.91 [6, 11] 
KlySly/V 
product of hydraulic conductivity of 
lymphatic wall and surface area of vessels 
per unit volume of tissue 
(Pa·s)
-1 
0 4.17×10
-7
 [7, 11] 
ply pressure in lymphatics Pa 0 0 [11, 23] 
Dc cell density 10
5
cell/m
3 
1×10
10 
- 
estimated  
[24] 
VT total tumour volume m
-3
 5×10
-5
 - 
estimated 
[9] 
VB total blood volume in body m
-3
 5×10
-2
 5×10
-2
 [9, 25] 
 
512 
Table A-7. Parameters for liposome 
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Symbol Parameter Unit 
in 
Tumour 
in Normal 
Tissue 
Source 
Po permeability m/s 3.42×10
-9
 8.50×10
-10
 [26, 27] 
h 
thermo-enhanced fold of permeability 
in tumour 
 71 - 
estimated based on 
[9, 28] 
D diffusivity m
2
/s 9.0×10
-12
 5.8×10
-12 
[27, 29] 
σl 
osmotic reflection coefficient of 
liposome 
 0.95 1.0 
estimated based on 
[6, 30] 
A1 parameter of pharmacokinetic model  kg/m
3 
6.90×10
-3
 6.90×10
-3
 [18] 
A2 parameter of pharmacokinetic model kg/m
3 
1.22×10
-2
 1.22×10
-2
 [18] 
k1 compartment clearance rate s
-1 
8.37×10
-5
 8.37×10
-5
 [18] 
k2 compartment clearance rate s
-1 
4.17×10
-6
 4.17×10
-6
 [18] 
krel_37
o
C release rate at 37
o
C s
-1 
0 - assumption 
krel_42
o
C release rate at 42
o
C s
-1 
0.0078 - [31] 
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Table A-8. Parameters for doxorubicin 
 515 
Symbol Parameter Unit 
Free 
Doxorubicin 
Bound 
Doxorubicin 
Source 
PTumour_o permeability in tumour  m/s 3.00×10
-6
 7.80×10
-9
 [11, 32] 
h 
thermo-enhanced fold of 
permeability in tumour 
 2.56 - [33] 
PNormal 
permeability in normal 
tissue 
m/s 3.75×10
-7
 2.50×10
-9
 [11, 32] 
DTumour diffusivity in tumour m
2
/s 3.40×10
-10
 8.89×10
-12  derived from 
[10, 21, 34-36] 
DNormal diffusivity in normal tissue m
2
/s 1.58×10
-10
 4.17×10
-12
 
derived from 
[10, 21, 34-36] 
σd 
osmotic reflection 
coefficient of doxorubicin 
 0.15 0.82 [6, 11] 
ka 
association rate with 
protein  
s
-1
 0.833 - estimated [24] 
kd 
disassociation rate with 
protein 
s
-1
 - 0.278 estimated [24] 
Vmax 
rate of trans-membrane 
transport 
kg/10
5
cells 
s 
4.67×10
-15
 - [10, 37] 
ke 
michaelis constant for 
transmembrane transport 
kg/m
3 
2.19×10
-4
 - [10, 37] 
ki 
michaelis constant for 
transmembrane transport 
ng/10
5
cells 1.37×10
-12 
- [10, 37] 
fmax cell-kill rate constant s
-1 
1.67×10
-5
 - [38] 
EC50 
drug concentration 
producing 50% of fmax 
kg/10
5
cells 5×10
-13
 - [38] 
Dose doxorubicin dose kg
 
8.56×10
-5
 - [11, 39] 
A 
parameter of 
pharmacokinetic model 
m
-3
 74.6 74.6 [10, 40] 
B 
parameter of 
pharmacokinetic model 
m
-3
 2.49 2.49 [10, 40] 
C 
parameter of 
pharmacokinetic model 
m
-3
 0.552 0.552 [10, 40] 
α compartment clearance rate s-1 2.43×10-3 2.43×10-3 [10, 40] 
β compartment clearance rate s-1 2.83×10-4 2.83×10-4 [10, 40] 
γ compartment clearance rate s-1 1.18×10-5 1.18×10-5 [10, 40] 
kp 
cell proliferation rate 
constant 
s
-1 
3.0×10
-6
 - estimated [24] 
kg 
cell physiological 
degradation rate 
s
-1
 3.0×10
-16
 - estimated [24] 
CLtumour 
clearance rate of 
doxorubicin in tumour 
s
-1
 2.43×10
-3
 0 [9, 40, 41] 
CLnormal_tissue 
clearance rate of 
doxorubicin in normal 
tissue 
s
-1
 2.43×10
-3
 0 [9, 40, 41] 
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